Statement 05/25/2015. BIlastine in Japan: ready for registration.
Statement 05/18/2015. Faes Farma has licensed a pharmaceutical product from its portfolio in Spain.
Statement 02/27/2015. Faes Farma increases its net probit by 12.1% in 2014.
Statement 05/14/2014. Bilastine in Canada: signing of a license agreement.
Statement 10/29/2013. Joint-venture in Mexico.
Statement 07/24/2013. January-June results.
Statement 12/13/2012. Faes Farma licences bilastine for South Africa and Argentina.
Statement 07/24/2012. Today Faes Farma S.A. and Taiho Pharmaceutical CO., LTD. have signed in Japan a license agreement for the development and marketing of bilastine in the Japanese market.
Statement 07/17/2012. January-June results.
Statement 07/02/2012. FAES FARMA S.A. informs of the approval of bilastine in Mexico and hidrosmine in Venezuela.
Statement 06/14/2012. Payment of the complementary dividend of 2011.
Statement 04/26/2012. FAES FARMA and INVIDA (MENARINI Group) sign an agreement to commercialize bilastine in 17 countries in Asia - Pacific.
Statement 02/07/2012. FAES FARMA and PFIZER sign a new agreement to extend bilastine's licence to another 21 Latin American markets.
Statement 01/24/2012. Bilastine's launch in Brazil.
Statement 01/18/2012. FAES FARMA S. A. will market 3 products from Laboratorios Salvat, S.A. in 5 Latin American countries, within its expansion plan in this region.
Statement 12/20/2011. Payment of the first interim 2011 dividend of Euros 0.02.
Statement 11/10/2011. FAES FARMA licences Bilastine´s marketing rights in Indonesia.
Statement 09/29/2011. Listing of shares from the Share Capital Increase.
Statement 03/29/2011. Faes Farma markets bilastine under the brand Bilaxten® in Spain.
Statement 02/24/2011. Payment of the second interim dividend of 2010.
Statement 01/12/2011. GSK signs license to market bilastine in Spain and Poland.
Statement 12/23/2010. Bilastine is approved in two other countries.
Statement 12/02/2010. Bilastine is approved in eight European countries.
Statement 12/28/2009. FAES FARMA licences Bilastine's marketing rights to NYCOMED in Brazil.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you deactivate this cookie we will not be able to save your preferences.This means that every time you visit this website you will have to activate or deactivate cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please, first activate the strictly necessary cookies so that we can save your preferences!